Inhibikase Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Stock-based Compensation - Additional Information (Details)

Stock-based Compensation - Additional Information (Details) - USD ($)				1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 21, 2026	Feb. 21, 2025	Jan. 03, 2025	Feb. 28, 2025	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025	Mar. 25, 2026	Jan. 26, 2026	Jan. 01, 2026	Dec. 31, 2025	Jun. 07, 2024
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Percentage of Common Stock Outstanding, During Period Increase (Decrease)			4.00%				4.00%
Common stock shares reserved for issuance			27,453,993		3,372,704		3,372,704					5,197,330
Stock-based compensation expense					$ 5,527,808	$ 4,525,206	$ 16,433,584	$ 10,776,144
Compensation cost related to non-vested option awards not yet recognized					49,200,000		$ 49,200,000
Weighted average remaining vesting period							2 years 4 months 28 days
Options, Grants in Period, Weighted Average Fair Value							$ 1.59	$ 1.75
CorHepta Pharmaceuticals [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of Shares, Granted		2,489,030
Restricted Stock [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of Shares, Forfeited	664,089
Restricted Stock [Member] \| CorHepta Pharmaceuticals [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense					0	$ 700,000	$ 400,000	$ 1,800,000
Restricted share issued				1,660,222
Service based vesting shares				996,133
Fair Value Of Restricted Stock Granted							4,900,000
Unrecognized Compensation Cost					$ 0		$ 0
Employee stock plan
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of Shares, Granted							13,667,142	27,225,823
Stock option, strike price					$ 1.99	$ 2.34	$ 1.99	$ 2.34
Stock option, aggregate grant date fair value						$ 54,700,000		$ 54,700,000
Performance-based options, Granted								2,056,049
Performance-based options, weighted average strike price								$ 2.35
Employee stock plan \| Employee Stock Option
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock option, aggregate grant date fair value					$ 21,700,000		$ 21,700,000
Two Thousand And Twenty Plan [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Plan modification							41,386,723
Common stock shares reserved for issuance			27,453,993							3,000,000	6,969,206		2,500,000
2026 Inducement Plan [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Common stock shares reserved for issuance									4,000,000